AstraZeneca's Datopotamab Deruxtecan Applications Validated In EU For Lung Cancer, Breast Cancer

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) said that the European Medicines Agency or EMA has validated two marketing authorisation applications for the companies' datopotamab deruxtecan or Dato-DXd in two types of cancer. https://www.nasdaq.com/articles/astrazenecas-datopotamab-deruxtecan-applications-validated-in-eu-for-lung-cancer-breast